"Key Scientific Drivers Behind Probiotic and Prebiotic Applications"



International Symposium of the International Scientific Association of Probiotics and Prebiotics

June 5-6, 2018, Furama Riverfront Hotel, Singapore

### If You Could Design A Probiotic, What Would It Look Like?



#### Sarah LEBEER Belgium

Organised by:





Singapore Society for Microbiology and Biotechnology Meeting Sponsors: Platnium

Yakult

Silver



Conference Secretariat & Housing Bureau:

ace:daytons





### If You Could Design A Probiotic, What Would It Look Like?

Prof. Sarah Lebeer



06/06/2018



### What are probiotics?



#### EXPERT CONSENSUS DOCUMENT

#### The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

REVIEWS GASTROENTEROLOGY

Colin Hill, Francisco Guarner, Gregor Reid, Glenn R. Gibson, Daniel J. Merenstein, Bruno Pot, Lorenzo Morelli, Roberto Berni Canani, Harry J. Flint, Seppo Salminen, Philip C. Calder and Mary Ellen Sanders

Box 1 | Consensus panel recommendations for the scope of probiotics

- Retain the FAO/WHO definition<sup>1</sup> for probiotics, with a minor grammatical correction as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host"; inconsistences between the Expert Consultation<sup>1</sup> and the FAO/WHO Guidelines<sup>2</sup> were clarified
- Include in the framework for definition of probiotics microbial species that have been shown in properly controlled studies to confer benefits to health

### Objectives: predict & explain





Which properties?



# Microbial probiotic properties?



Available online at www.sciencedirect.com

ScienceDirect



#### Shared mechanisms among probiotic taxa: implications for general probiotic claims Mary Ellen Sanders<sup>1</sup>, Andrew Benson<sup>2</sup>, Sarah Lebeer<sup>3</sup>,

Daniel J Merenstein<sup>4</sup> and Todd R Klaenhammer<sup>5</sup>





Available online at www.sciencedirect.com





## Identification of probiotic effector molecules: present state and future perspectives

Sarah Lebeer<sup>1</sup>, Peter A Bron<sup>2</sup>, Maria L Marco<sup>3</sup>, Jan-Peter Van Pijkeren<sup>4</sup>, Mary O'Connell Motherway<sup>5</sup>, Colin Hill<sup>5</sup>, Bruno Pot<sup>6,7</sup>, Stefan Roos<sup>8</sup> and Todd Klaenhammer<sup>9</sup>



## Probiotics = "bags of effector molecules"

Figure 1



### Shared probiotic functions = CORE

Shared core probiotic mechanisms Sanders et al. 209

Current Opinion in Biotechnology 2018, 49:207-216



Shared probiotic mechanisms and their taxonomic distribution.

## Current focus = LAB



genus - Streptococcus - Escherichia Staphylococcus Mycobacterium - Salmonella Pseudomonas - Klebsiella Bacillus - Acinetobacter Vibrio Campylobacter Listeria 2005 2010 2015 Date

> *Lactobacillus*: the most commonly sequenced non-pathogenic 'genus'

https://swuyts.wordpress.com/



Long history of safe use in fermented foods

## Rationale for probiotic strain selection



### Simplied overview health effects

#### Box 1 Probiotic mechanisms of action from a host perspective.

While the major part of the manuscript is focused on probiotic mechanisms of action from a microbiological perspective, possible molecular mechanisms of action of probiotics from a host perspective can be broadly divided into the following categories:

- (1) Modulation of the composition and activity of the indigenous microbiota at least temporarily
- (2) Enhancement of epithelial barrier function
- (3) Modulation of the immune system
- (4) Modulation of systemic metabolic responses
- (5) Signaling via the central nervous system

e.g. bile salt hydrolases e.g. GABA





# Check blogs

THE NEED TO IMPROVE IN VITRO PROBIOTICS	TESTING OF FUTURE
25KU K6980 4748 1.80 MENDA	Infographics, Videos, and Additional Information Videos <b>HOW TO CHOOSE A PROBIOTIC</b>
APRIL 4, 2018 THE NEED TO IMPROVE IN VITRO TESTING OF FUTURE PROBIOTICS	HEALTH BENEFITS OF PROBIOTICS
cdrf.org/2018/03/01/probiotic-screening-vitro-tests-informative/	m 🕁
cdrf.org/2018/03/01/problotic-screening-vitro-tests-informative/  CALIFORNIA DARABEL	
Image: Contract of the second seco	

## Challenge probiotic properties



# My experience: LGG as model

#### TOOLBOX



- Genome editing tools: mostly loss-of function mutants
- Biochemical tools: extraction & characterization of cell surface & secreted molecules (EPS, pili, secreted (glyco) proteins
- Comparative genomics of lactobacilli
- Microbiome analysis mainly by 16S amplicon sequencing
- Array of phenotypic tests: niche adaptation, metabolism, adhesion, immunomodulation, formulation, etc.
- In vivo tests: mice models & human intervention studies (urogenital, skin & upper respiratory tract >< gut)</li>



## LGG : documented health benefits

- Promotion of gastro-intestinal health in children and adults
- Reduce respiratory infections in children
- Lower eczema risk in family with history
- Protect hospitalized patients against ventilatorassociated pneumonia
- Promote oral health
- Vaccine adjuvans (e.g. polio)

## Antimicrobial activity LGG



15

## Gut microbiome modulation capacity

OPEN



#### ARTICLE DOI: 10.1038/s41467-018-03157-4

Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by *Lactobacillus* supplementation

Juliana Durack<sup>1</sup>, Nikole E. Kimes<sup>1,4</sup>, Din L. Lin<sup>1</sup>, Marcus Rauch<sup>1,5</sup>, Michelle McKean<sup>2</sup>, Kathryn McCauley<sup>1</sup>, Ariane R. Panzer<sup>1</sup>, Jordan S. Mar<sup>1,6</sup>, Michael D. Cabana<sup>2,3</sup> & Susan V. Lynch<sup>1</sup>



Cotaber 2017, Volume 56, <u>http://pp.2265-22531Citt.as</u> Probiotics modulate gut microbiota and health status in Japanese cedar pollinosis patients during the pollen season

#### Authors Authors and affiliation

European Journal of Nutrition

Gaku Harata 🖂 , Himanshu Kumar, Fang He 🖂 , Kenji Miyazawa, Kazutoyo Yoda, Manabu Kawase, Akira Kubota, Masanu Hiramatsu, Samuli Rautava, Seppo Salminen



#### RESEARCH ARTICLE

*Lactobacillus rhamnosus* GG Intake Modifies Preschool Children's Intestinal Microbiota, Alleviates Penicillin-Associated Changes, and Reduces Antibiotic Use

Katri Korpela<sup>1</sup>\*, Anne Salonen<sup>1</sup>, Lauri J. Virta<sup>2</sup>, Minna Kumpu<sup>3</sup>, Riina A. Kekkonen<sup>3</sup>, Willem M. de Vos<sup>1,4</sup>

1 Department of Bacteriology and Immunology, Immunobiology Research Programme, Faculty of Medicine, University of Helsinki, Finland, 2 Research Department, Social Insurance Institution, Turku, Finland, 3 R8D, Valio Limited, Helsinki, Finland, 4 Laboratory of Microbiology, Wageningen University, Wageningen, the Netherlands.

\* katri.korpela@helsinki.fi

### LGG effector molecules $\rightarrow$ host cells



Figure 2 Molecular interactions of LGG with intestinal epithelial cells. LTA as a MAMP interacts with TLR2-6, activating NF-κ signaling [43]. Secreted protein Msp2/p40 induces release of HB-EGF that causes phosphorylation of EGF-activating downstream protein kinase C (PKC) and phosphoniositide 3-kinase (PAB) -Akt signaling [51,53,54]. A recent human duodenal transcriptome study indicates that JUN and STAT4 transcription factors play a central role in downstream signaling after consumption of LGG, leading to mainly T<sub>4</sub>1 cytokine production and activating pathways involved in cellular growth and proliferation, wound healing, angiogenesis, interferon-mediated responses, calcium signaling and ion homeostasis [92]. Adapted from [96] Epithelial interaction

+ EPS

Segers and Lebeer Microbiol Cell Factories 2014, 13(Suppl 1):57 http://www.microbiologilactories.com/content/11/51/57 MICROBIAL CELL

**Open Access** 

Towards a better understanding of Lactobacillus rhamnosus  $\mathsf{GG}$  - host interactions

Marijke E Segers<sup>1,2</sup>, Sarah Lebeer<sup>1,2\*</sup>

#### Segers & Lebeer, 2014, MCF

6

### SpaCBA pili as important modulators



Segers & Lebeer, 2014

Towards a better understanding of Lactobacillus

Towards a better understanding of Lactobacillu rhamnosus GG - host interactions

MICROBIAL CELL

### Presence of pili determines interaction



\*\*\* Total associated bacteria \*\*\* Adhered bacteria \*\* \*\*\* Phagocytosed bacteria 45 \*\* \*\*\* 40 35 Percentage (%) 30 25 20 15 10 LGG WT spaCBA MT welE MT L. lactis GRS1185 \*\*p < 0.01 MG1363 \*\*\*p < 0.001

IECs



Functional Analysis of *Lactobacillus rhamnosus* GG Pili in Relation to Adhesion and Immunomodulatory Interactions with Intestinal Epithelial Cells

Sarah Lebeer,<sup>a,b</sup> Ingmar Claes,<sup>a</sup> Hanne L. P. Tytgat,<sup>a</sup> Tine L. A. Verhoeven,<sup>a</sup> Eyra Marien,<sup>a</sup> Ingemar von Ossowski,<sup>c</sup> Justus Reunanen,<sup>c</sup> Alri Palva,<sup>c</sup> Willem M. de Vos,<sup>c,d</sup> Sigrid C. J. De Keersmaecker,<sup>a</sup> and Jos Vanderleyden<sup>a</sup>

Centre of Microbial and Plant Genetics, KU. Leuven, Leuven, Belgium<sup>1</sup>; Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium<sup>1</sup>; Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland<sup>1</sup>; and Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands<sup>1</sup>

#### macrophages



#### Piliation of *Lactobacillus rhamnosus* GG Promotes Adhesion, Phagocytosis, and Cytokine Modulation in Macrophages

Cynthia E. Vargas García,<sup>a,b</sup> Mariya Petrova,<sup>a,b</sup> Ingmar J. J. Claes,<sup>a,b</sup> Ilke De Boeck,<sup>a,b</sup> Tine L. A. Verhoeven,<sup>a</sup> Ellen Dilissen,<sup>c</sup> Ingemar von Ossowski,<sup>d</sup> Airi Palva,<sup>d</sup> Dominique M. Bullens,<sup>c</sup> Jos Vanderleyden,<sup>a</sup> <sup>©</sup>Sarah Lebeer<sup>a,b</sup>

KU Leuven, Centre of Microbial and Plant Genetics, Hevelee, Belgium<sup>4</sup>; University of Antwerp, Department of Bioscience Engineering, Research Group Environmental Ecology and Applied Microbiology, Antwerp, Belgium<sup>4</sup>; KU Leuven, Laboratory of Pediatric Immunology, Leuven, Belgium<sup>4</sup>; University of Helsinki, Department of Veterinary Biosciences, Helsinki, Finland<sup>4</sup> SOCIETY FOR

#### Comparative genomics: how unique? **ystems**° 48.0 AMERICAN

#### Large-Scale Phylogenomics of the Lactobacillus casei Group Highlights **Taxonomic Inconsistencies and Reveals** Novel Clade-Associated Features

Sander Wuyts,<sup>a</sup> Stijn Wittouck,<sup>a</sup> Ilke De Boeck,<sup>a</sup> Camille N. Allonsius,<sup>a</sup> Edoardo Pasolli, <sup>b</sup> Picola Segata, <sup>b</sup> Sarah Lebeer<sup>a</sup>



# SpaC presence in *Lactobacillus* 'genus'



Lactobacillus_gallinarum	Lactobacillus_gasseri	Lactobacillus_helveticus	Lactobacillus_iners	Lactobacillus_jensenii	Lactobacillus_johnsonii	Lactobacillus_kefiranofaciens	Lactobacillus_kefiri
Lactobacillus_kunkeei	Lactobacillus_lindneri	Lactobacillus_mucosae	Lactobacillus_murinus	Lactobacillus_parabuchneri	Lactobacillus_paracasei	Lactobacillus_paracollinoides	- Lactobacillus_paraplantarum
							-
Lactobacillus_pentosus	Lactobacillus_plantarum	Lactobacillus_reuteri	Lactobacillus_rhamnosus	Lactobacillus_ruminis	Lactobacillus_sakei	Lactobacillus_salivarius	Lactobacillus_sanfranciscensis
				-			1

Lactobacillus\_brevis Lactobacillus\_casei Lactobacillus\_coryniformis Lactobacillus\_crispatus Lactobacillus\_curvatus Lactobacillus\_delbrueckii Lactobacillus\_fermentum Lactobacillus\_fructivorans

## What can we learn from LGG?

- Key effector molecules
  - Pili
  - Lactic acid
  - Msp1/2, LTA, EPS, CpG DNA
  - + highly robust strain= survives various stresses (e.g. formulation) >< vagina (GR-1)
- Causal molecules? Test mutants or molecules in humans
  - E.g. spontaneous pili mutant (Prof. Willem de Vos)
  - E.g. Msp2/p40 (Prof. Polk, Prof. Yan, USA)
  - Crispr-Cas mutagenesis & other recombineering tools being implemented
- Validation in larger scale human studies
  - Multi-omics approaches holistic view translation back to mechanisms
  - Patient stratification, dosing, formulation, timing of intervention, ....

# Probiotic design

#### Probiotic

#### Suitable probiotic?

- · Previous clinical trials
- Known modes of action
- Probiotic effector molecules
- Adaptation factors
- Commercial availability

#### Formulation?

- Site of administration
- Desired host response
- Pay attention to growth phase & cell surface factors (pili, EPS, Msp1/Msp2 ...)

#### Dosage?

- Site & time of administration
- Desired host response
- Formulation

#### HOST

#### Healthy host?

 Take broad 'bandwidth of human health' into account

#### Disease state? Safety check

- Integrity epithelial barrier
- Immuno-compromised host

#### Generic background?

- Stratify for potential responders
- PRR heterogeneity
- Genetics immune pathways
- Other host response genes

#### Microbiota?

• Age

Dysbiosis

Use of 'omics' & molecular tools to substantiate effects

Segers and Lebeer Microbial Cell Factories 2014, 13(Suppl 1 http://www.microbialcellactories.com/content/13/S1/S7 MICROBIAL CELL

Towards a better understanding of *Lactobacillus* rhamnosus GG - host interactions

### Translation outside gut



Lebeer et al., 2008, MMBR

### Acknowledgements

#### All collaborators

Prof. J. Vanderleyden Prof. W. de Vos Prof. G. Reid Prof. L. De Vuyst Prof. T. Van de Wiele Prof. Ceuppens Prof. Bullens Prof. Bullens Prof. Hellings Prof. Donders Prof. Lambert Prof. Vanderveken Prof. Kiekens



International Scientific Association for Probiotics and Prebiotics





ENDERIC Environmental Ecology and Applied Microbiology University of Antwerp

fwo



ILSI

www.procureproject.be